Skip to main content

Table 3 Adjusted overall survival and progression-free survival of patients by multivariate Сox regression analyses

From: A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study

Variables

OS

PFS

HR (95% CI)

p-value

HR (95% CI)

p-value

Neoadjuvant chemotherapy

1.367 (0.806–2.319)

0.246

1.136 (0.770–1.678)

0.521

Maintenance therapy with I3C

0.272 (0.147–0.502)

< 0.0001

0.309 (0.202–0.472)

< 0.0001

Maintenance therapy with I3C and EGCG

0.244 (0.150–0.396)

< 0.0001

0.241 (0.172–0.339)

< 0.0001

PСI (> 25 vs ≤ 25)

2.829 (1.813–4.415)

< 0.0001

2.114 (1.589–2.812)

< 0.0001

FIGO stage (IV vs III)

9.642 (5.963–15.592)

< 0.0001

6.953 (4.744–10.190)

< 0.0001

Secondary debulking surgery

< 0.0001 (< 0.0001- > 1.0х103)

0.930

1.277 (0.875–1.862)

0.205

  1. OS overall survival, PFS progression-free survival, HR hazard ratio, 95% CI 95% confidence interval, I3C indole-3-carbinol, EGCG epigallocatechin-3-gallate, PCI peritoneal cancer index, FIGO International Federation of Gynecology and Obstetrics
  2. NOTE. Bold font indicates p < 0.05